Thromboprophylaxis of elderly patients with AF in the UK: An analysis using the General Practice Research Database (GPRD) 2000-2009

Heart

Volumn 99, Issue 2, 2013, Pages 127-132

  Scowcroft, Anna C E ^a   Lee, Sally ^a   Mant, Jonathan ^b  

^a BOEHRINGER INGELHEIM LTD   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; BODY MASS; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DEMENTIA; DISEASE ASSOCIATION; DRUG USE; FEMALE; GENDER; GENERAL PRACTICE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; THROMBOSIS; THROMBOSIS PREVENTION; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNITED KINGDOM;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; GENERAL PRACTICE; GREAT BRITAIN; HUMANS; INCIDENCE; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS; TREATMENT OUTCOME;

EID: 84871750425     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-302843     Document Type: Article

References (30)

1. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57.
2. Lip GYH, Lim HS. AF and stroke prevention. Lancet 2007;6:981-93.
3. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5.
4. Tsang TS, Gersh BJ. Atrial fibrillation: an old disease, a new epidemic. Am J Med 2002;113:432-5.
5. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67.
6. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429.
7. Lip GYH, Nieuwlaat R, Pisters R, et al . Refining clinical risk stratification for predicting stroke and thromboembolism in AF using a novel risk factor-based approach. The Euro heart Survey on AF. Chest 2010;137:263-72.
8. Carlsson AC, Wandell P, Sundquist K, et al. Differences and time trends in drug treatment of atrial fibrillation in men and women and doctors' adherence to warfarin therapy recommendations : A Swedish study of prescribed drugs in primary care in 2002 and 2007. Eur J Clin Pharmacol 2012. doi: 10.1007/s00228-012-1322-6
9. Sandhu R, Bakal AB, Ezekowitz JA, et al. Risk stratification schemes, anticoagulation use and outcomes: the risk-treatment paradox in patients with newly diagnosed non-valvular atrial fibrillation. Heart 2011;97:2046-50.
10. National Institute for Health & Clinical Excellence (NICE). Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation. Technology Appraisal TA249. March 2012. http://guidance.nice.org.uk/TA249/Guidance/pdf/English(accessed Mar 2012).
11. Darkow T, Vanderplas AM, Lew KH, et al. Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system. Curr Med Res Opin 2005;21:1583-94.
12. Waldo AL, Becker RC, Tapson VF, et al. NABOR Steering Committee. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol 2005;46:1729-36.
13. Hylek EM, D'Antonio J, Evans-Molina C, et al. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 2006;37:1075-80.
14. Srivastava A, Hudson M, Hamoud I, et al. Examining warfarin underutilization rates in patients with atrial fibrillation: detailed chart review essential to capture contraindications to warfarin therapy. Thromb J 2008;6:6.
15. Chan PS, Maddox TM, Tang F, et al. Practice-level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PINNACLE program). Am J Cardiol 2011;108:1136-40.
16. Sinnaeve PR, Brueckmann M, Clemens A, et al. Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation. J Intern Med 2012;27:15-24.
17. De Wilde S, Carey IM, Emmas C, et al. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart 2006;92:1063-70.
18. Rash A, Downes T, Portner R, et al. A randomised controlled trial of warfarin versus aspirin for stroke prevention on octogenarians with AF (WASPO). Age Ageing 2007;36:151-6.
19. Mant J, Hobbs R, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with AF (the Birmingham AF Treatment of the Aged Study BAFTA): a randomised controlled trial. Lancet 2007;370:493-503.
20. Loewen P, Dahri K. Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules. Ann Haematol 2011;90:1191-200.
21. García Rodríguez LA, Pérez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45:419-25.
22. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess one-year risk of bleeding in AF patients: The Euro heart Survey. Chest 2010;138:1093-100.
23. Ruigomez A, Johansson S, Wallander M, et al. Incidence of Chronic AF in general practice and its treatment pattern. J Clin Epidemiol 2002;55:358-63.
24. Murphy NF, Simpson CR, Jhund PS, et al. A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. Heart 2007;93:606-12.
25. Humphries KH, Kerr CR, Connolly SJ, et al. New-onset atrial fibrillation: sec differences in presentations, treatment, and outcome. Circulation 2001;103:2365-70.
26. Tsadok MA, Jackevicius CA, Rahme E, et al. Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. JAMA 2012;307:1952-8.
27. Horsfield P, Teasdale S. Generating information from electronic patient records in general practice: a description of clinical care and gender inequalities in coronary heart disease using data from over two million patient records. Inform Prim Care 2003;11:137-44.
28. Ahmad Y, Lip GY. Stroke Prevention in Atrial Fibrillation: Where are We Now? Clin Med Insights Cardiol 2012;6:65-78.
29. Bungard TJ, Ghali WA, Teo KK, et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000;160:41-6.
30. Khan TI, Kamali F, Kesteven P, et al. The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. Br J Haematol 2004;126:557-64.